See every side of every news story
Published loading...Updated

Vivani issues positive preclinical weight loss data for NPM-139 semaglutide implant

Summary by bariatricnews.net
Vivani Medical has announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in people with obesity and overweight. These results reinforce the company’s commitment to addressing chronic weight management and other chronic diseases by leveraging its proprietary NanoPortal implant technology which is designed to enable smooth and steady delivery of therapeutic molecules inc…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

bariatricnews.net broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.